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The blood-brain barrier (BBB) is a biological barrier that protects the brain from 
neurotoxic agents and regulates the influx and efflux of molecules required for 
its correct function. This stringent regulation hampers the passage of brain 
parenchyma-targeting drugs across the BBB. BBB shuttles have been proposed 
as a way to overcome this hurdle since these peptides can not only cross the 
BBB but also carry molecules which would otherwise be unable to cross the 
barrier unaided. 
Here we developed a new high-throughput screening methodology to identify 
new peptide BBB shuttles in a broadly unexplored chemical space. By 
introducing D-amino acids, this approach screens only protease-resistant 
peptides. This methodology combines combinatorial chemistry for peptide 
library synthesis, in vitro models mimicking the BBB for library evaluation, and 
state-of-the-art mass spectrometry techniques to identify those peptides able to 
cross the in vitro assays. BBB shuttle synthesis was performed by the mix-and-
split technique to generate a library based on the following: Ac-D-Arg-XXXXX-
NH2, where X were: D-Ala (a), D-Arg (r), D-Ile (i), D-Glu (e), D-Ser (s), D-Trp (w), 
or D-Pro (p). The assays used comprised the in vitro cell-based BBB assay 
(mimicking both active and passive transport) and the PAMPA (mimicking only 
passive diffusion). The identification of candidates was determined using a two-
step mass spectrometry approach combining LTQ-Orbitrap and Q-trap mass 
spectrometers.  
Identified sequences were postulated to cross the BBB models. We 
hypothesized that some sequences cross the BBB through passive diffusion 
mechanisms and others through other mechanisms, including paracellular flux 
and active transport.  
These results provide a new set of BBB shuttle peptide families. Furthermore, 
the methodology described is proposed as a consistent approach to search for 
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An estimated 1.5 billion people suffer from CNS diseases worldwide. To tackle 
such diseases, there is an urgent need not only for new therapeutics but also 
for systems that efficiently deliver therapeutics to their site of action. The blood-
brain barrier (BBB) is located in the brain capillaries, and it is formed by 
endothelial cells, highly influenced by astrocytes, perycites and other glial cells. 
Features such as tight junctions , few endocytotic vesicles and high metabolic 
activity allows the BBB to control the passage of molecules from the blood 
stream to the brain parenchyma, thus protecting the brain from potential 
neurotoxic substances circulating in the blood.  
Two groups of transport mechanisms take place in the BBB: passive transport 
mechanisms (i.e. paracellular flux and passive diffusion) and active transport 
mechanisms (including receptor-mediated transcytosis, carrier-mediated 
transcytosis and adsorptive-mediated transcytosis [1]).  
The effectiveness of drugs for CNS diseases depends not only on their 
therapeutic effect but also on efficient delivery to their site of action. To this 
purpose, invasive [2,3] and pseudo-invasive [4] strategies are highly 
discouraged due to sever secondary effects and sequelae. A promising 
approach to deliver drugs to the brain is the use of BBB shuttles, also called the 
Trojan horse strategy [5,6], through intravenous injection. This strategy involves 
linking a drug unable to cross the BBB unaided to a BBB shuttle—a molecule 
that can cross this barrier. Ideally, this construct (BBB shuttle−drug) should 
cross the BBB together, thereby facilitating the uptake of the drug into the brain 
parenchyma. Ideally, a universal BBB shuttle should assist the passage of any 
molecule attached to it. Since passive diffusion relies on physicochemical 
properties, linkage of a drug (henceforth cargo) could dramatically affect shuttle 
efficiency. Although successful and promising passive shuttles have been 
described [7-11], BBB shuttles using active transport mechanisms are the 
molecules of choice to launch this shuttle strategy. Targeting highly expressed 
BBB receptors such as transferrin, lactoferrin, insulin, leptin receptors, and the 
LDL-receptor related protein 1 and 2 with the aim to achieve drug transport 
across the BBB by means of receptor-mediated transcytosis might be the most 
effective strategy.  
Historically, peptides have been overlooked as effective therapeutics mainly 
because of their peptidase lability, which basically ruled out their use as efficient 
therapeutics or part of therapeutic constructs. However, in recent years it has 
been demonstrated that peptides are a feasible alternative, being especially 
suited to mimic and/or adapt to active sites and thus effectively match the 
pockets of receptors and transporters. Specifically focusing on BBB shuttles, 
peptides have emerged as a consistent alternative [12-15]. A variety of peptides 
have been described to be efficient BBB shuttles. Angiopep2 has reached 
Phase II in clinical trials [12]. Other examples of molecules with potential to 
become BBB shuttles are SynB1, SynB3, penetratin and TAT peptides, as well 
as THRre-peptide and apamin derivatives [13,14,16-18].  
A variety of strategies can be envisaged to discover and/or design novel BBB 
shuttles. From natural products or chemically modified molecules to high-
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throughput screening of molecular libraries, including chemically synthesized 
strategies or display technologies [19]. To the best of our knowledge, to date, 
there are no examples of peptide BBB shuttles designed through a structure-
based approach.  
Here we propose to search for water-soluble and protease-resistant BBB-
shuttle peptides using a high-throughput screening methodology that combines 
peptide combinatorial chemistry, in vitro cellular BBB models, and state-of-the-
art mass spectrometry. 
 
Results and discussion 
Peptide library design and synthesis 
A mix-and-split method was used to synthesize the peptide library [20]. This 
approach enables the synthesis of peptide mixtures comprising permutations of 
amino acids. The number of amino acid residues (m) in which variability is 
introduced in each peptide within the library and amino acid variability (r) on 
each peptide residue determine the total number of peptides in the library,	? =
??. To assess library size, combinations of r and m values were evaluated. 
Eventually, m = 5 and r = 7 values leading to a library comprising 16.807 
peptides were selected to synthesize our peptide library (see Section S1 in 
Supporting Information). On the basis of physicochemical and statistical 
parameters, as well as on synthetic performance in order to minimize coupling 
side reactions, a set of seven amino acids comprising D-tryptophan, D-arginine, 
D-alanine, D-glutamic acid, D-serine, D-isoleucine and D-proline  was selected 
(Table 1). 
Tryptophan is a fluorescent amino acid that plays a key role in many potential 
hot spots for protein-surface molecular recognition. Arginine is also described to 
have many potential interactions (electrostatic, H-bond) and is relevant for 
molecular recognition. Moreover, with a pI = 10.76, arginine has a positive 
charge in physiological pH. It is also described as a crucial residue for peptides 
able to cross membranes. Alanine is an abundant residue in natural systems. 
Since this amino acid has a small side chain, it can act as a spacer for distinct 
interaction sites on peptides. Glutamic acid contributes to negative charges and 
shows better synthetic performance than aspartic acid as it does not present 
side reactions leading to aspartimide formation. Serine is a polar non-charged 
amino acid that shows better performance on SPPS than β-branched threonine. 
Isoleucine is an aliphatic β-branched amino acid with a bulky side chain. It has a 
high tendency to form a β-sheet structure and has a higher presence than 
valine or leucine in active sites. Finally, proline is the only natural N-alkyl amino 
acid. It facilitates β-turns, and poly-Pro leads to particular structures. It has been 
described to play a crucial role in hydrophobic-hydrophobic interactions. 
The library design included the acetylation of the N-terminus and amidation of 
the C-terminus. Since these N- and C-terminus positions are regarded as 
potentially suitable sites to link eventual therapeutic cargos, acetyl and amide 
groups were used as the simplest cargo moieties. This approach allows to high-
throughput screen in physicochemical conditions that closely resemble those of 
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the final shuttle-moiety construct. In addition, we introduced a D-Arg moiety at 
the N-terminus of the 5 variable amino acid positions in the peptides to 
complement the library design, thus leading to a hexapeptide library. On the 
one hand, this approach ensures at least one position for charge stabilization 
for MS ionization. On the other hand, this singular Ac-D-Arg- fingerprint 
facilitates the identification of peptides within complex mixtures comprising 
endogenous peptides from in vitro cellular assays and in vivo assays. Library 
synthesis was performed by the mix-and-split methodology in SPPS. The 
synthetic workflow and a summary of the library design are provided in Figure 1, 
Library synthesis was validated through two methods. First, before whole library 
cleavage, single peptide analysis was performed by cleavage of single beads. 
Mix-and-split synthesis led to one-bead-one-compound (OBOC) libraries–
meaning that each bead contained several copies of the same peptide 
sequence. By cleaving peptides carried by single beads and the subsequent 
analysis by MALDI-TOF, we found that the peptides had the expected pattern 
(m = 5 + D-Arg + CH3COO- and composed only by the 7 amino acids used in 
the synthesis; homogeneous, single sequences were found, not presenting 
deletions). Second, once the library was cleaved from the resin, high-resolution 
mass spectrometry analysis was performed by direct infusion of the library on 
the FT-ICR mass spectrometer [23]. Quality control of the library synthesis was 
evaluated by comparison between the theoretically predicted library mass 
spectrum and the experimentally measured library mass spectrum as shown in 
Figure 2. Deviations such as peptides with a molecular weight lower or larger 
than that expected from the library design are useful to evaluate library quality. 
Both techniques are complementary tools for the quality control of combinatorial 
mix-and-split peptide libraries. 
Library assay using in vitro BBB models 
Two in vitro assays were used to test the Ac-D-Arg-library, namely the parallel 
artificial membrane permeability assay (PAMPA) and an in vitro cell-based BBB 
assay. PAMPA is an in vitro transport assay based on artificial phospholipid 
membranes that mimics only passive diffusion properties of the BBB (Figure 
3A).  
The PAMPA was run with a saturated solution of Ac-D-Arg-library in MilliQ water 
(neither commercial pION PAMPA buffer nor co-solvents were used). Samples 
were sonicated to ensure concentrations of peptides as high as possible, close 
to saturation, and pH was adjusted to 7.0. To eliminate non-water soluble 
peptides, samples were centrifuged and precipitate was removed. This step 
serves as a first screening stage to avoid selecting peptides that will have 
solubility problems on next stages of shuttle development process. The PAMPA 
was run for 4 h in triplicate. Acceptor (upper) and donor (lower) compartments 
and t0 aliquots were kept for analysis. A blank sample was run in parallel. 
In vitro cell-based BBB models are still far from fully mimicking the in vivo BBB, 
which is influenced by many other stimuli than those present in vitro. Several 
models based on cell co-cultures have been proposed with a variety of 
combinations of endothelial cells and astrocytes from distinct animals. These 
models have shown a significant correlation between in vitro and in vivo BBB 
permeability, although do not fully mimic the BBB. We selected the model 
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based on a co-culture of bovine brain endothelial cells and rat astrocytes, as 
shown in Figure 3B, as it is one of the most accepted and validated BBB 
models described to date [24,25]. This model mimics both passive diffusion 
properties and active transport mechanisms. 
The in vitro cell-based BBB assay was run with a , 1:10 dilution of the saturated 
solution of Ac-D-Arg-library in Ringer/HEPES buffer (buffer required for cell-
based BBB model). Dilution was applied to avoid high peptide concentrations to 
minimize cell stress and disruption of the in vitro BBB. The pH was adjusted to 
7.0. To eliminate non-water soluble peptides, samples were centrifuged and 
precipitate was removed. Lucifer yellow was added as an internal standard to 
each well. The in vitro cell model was run for 2 h at 37ºC in triplicate. Donor 
(apical) and acceptor (baso-lateral) compartments and t0 aliquot were kept for 
analysis. TEER measures (prior to the assay) of co-cultured cell layers of the in 
vitro cell-based assay were 125 ± 18 Ωcm2. A blank sample was run in parallel. 
Peptide identification by mass spectrometry 
The greatest challenge of this approach to discover novel BBB shuttles is the 
identification of peptides able to cross the in vitro BBB assays. We were 
confronted with a mixture of extremely similar peptides, especially those 
sequences with the same composition and that share similar physicochemical 
properties. Such similarity therefore hinders their differentiation. This complex 
peptide mixture can be analyzed on the basis of proteomic analysis, although a 
combination of mass spectrometry techniques should be considered. Mass 
spectrometry techniques were preferred over others such as pool sequencing 
method by Edman degradation since allow higher versatility on the screened 
libraries.  
While a stringent assay such as the in vitro cell-based BBB assay enormously 
reduces the number of peptides to be analyzed in the acceptor (baso-lateral) 
compartment, coupled chromatographic and mass spectrometric techniques are 
still required to fractionate the complexity of the acceptor mixture. 
However, from such similar mixtures, high retention time differences to separate 
peptides by chromatographic techniques are not expected to be sufficient, even 
working with isocratic gradients. In many cases, peptides will be simultaneously 
ionized and analyzed in the mass spectrometer. Mass spectrometry techniques 
provide m/z information about the molecules ionized, thus identifying all those 
with characteristic m/z signals in the peptide ion spectra, also called MS1. The 
high resolution and precision (10 ppm) of this advanced technique allows the 
unequivocal assignation of signals to molecular compositions. 
Molecular masses represent mostly a single amino acid composition, but in 
some cases combinations of pairs, trios or larger groups of amino acids may 
have the same overall mass and thus not be distinguishable with 10 ppm 
precision. In our library, the following combinations of amino acids led to 
indistinguishable compositions (10 ppm precision): (D-Ala)2-(D-Glu)1 and (D-
Ser)2-(D-Pro)1, 0.04 ppm; and (D-Glu)2-(D-Ile)2 and (D-Ala)2-(D-Arg)1-(D-Trp)1, 
2.75 ppm. Therefore it is critical not to assume that the same molecular mass 
denotes a single amino acid composition (from now on we will use the term 
peptide family to denote a single amino acid composition).  
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Indeed, each peptide family contains a diverse number of specific peptide 
sequences (family members) depending on the amino acid distribution within 
the sequence: from a single member where all amino acids are the same to 120 
members when each member differs (Table 2). 
Given that the members of a family share the same m/z and specific family 
members cannot be identified using solely MS1 spectrometric techniques, we 
designed an analytical MS strategy comprising two mass spectrometric levels.  
The first level of identification consisted of injecting the sample into an LTQ-
Orbitrap (coupled to LC) mass spectrometer. This first step focuses only on 
MS1 spectrum data and provides a clear picture of all precursor ions (in this 
case they can also be called peptide ions or molecular ions because no later 
fragmentation is performed) present in the sample. 
However, MS1 spectrometric techniques alone are unable to identify specific 
peptide sequences (family members). In this regard, MS1 spectra information 
allows the identification of specific molecular compositions (peptide families) in 
the sample.  To this purpose, we developed a computer program called 
Bibliopepfinder. We used this tool to sort LTQ-Orbitrap output data (MS1 
spectra peaks) that match peptide families of the synthesized library (see 
Section 2 in Supporting Information). 
This first identification level resulted in a LTQ-Orbitrap MS1 precursor ion list, 
which contained information only on the composition of peptides present in the 
sample, as shown in Figure 4. At this point, we focused our efforts on targeting 
a few selected families since the second identification level cannot be 
performed with diverse families at the same time. 
In the second identification level, we used single reaction monitoring (SRM) 
technology, now extensively used for targeted proteomic analysis [26]. For this 
purpose, triple quadrupole (QqQ) equipment was used, taking advantage of its 
high sensitivity. The combination of m/z settings on both the first and third 
quadrupoles of QqQ is referred to as transition. To filter the desired peptide 
parent ion, the m/z value of the first quadrupole is determined by the mass and 
the most abundant charge state of the targeted peptide. In the third quadrupole, 
one fragment ion (or daughter ion) is selected and thus a transition is defined. 
In contrast to a classical proteomic SRM approach—which monitors only a 
reduced set of transitions from a selected number of peptides—our analysis 
aimed to explore all the sequences from selected compositions (peptide 
families). For this purpose, we monitored the complete transition set of each 
sequence of the selected peptide composition. 
Transitions corresponding to all b and y ions from singly and doubly charged 
precursor ions were monitored. When enough transitions that define a 
sequence are found in the resulting spectrum, we can assure that this specific 
peptide sequence is present within the m/z LTQ-Orbitrap MS1 signal, and thus 
that it crosses the BBB in vitro assay.  
The QqQ equipment allows the monitoring of around 120 transitions per 
injection (considering a dwell time of 20 ms) [27]. Thereafter, few families can 
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be screened because there is not enough sample for recurrent injections 
(approximately 4-5 injections were performed per sample). For this reason, it is 
of paramount importance to have a rational selection criterion to choose the 
most promising families from the MS1 LTQ-Orbitrap list. 
To perform this selection, we formulated four requirements to be fulfilled by all 
candidate families in order to pass through to the second identification level 
(Table 3). First, the family has to be present in all in vitro assay triplicates. 
Second, their molecular peak must fulfil typical mass spectrometry fingerprint 
profile of peptide species in the MS1 LTQ-Orbitrap spectra: molecular and 
isotopic peaks must have a consistent and peptide-like profile (considering 
peptide masses between 500 a.m.u. and 1200 a.m.u.) [28] and, furthermore, it 
must be confirmed that the molecular peak is indeed a molecular peak and not 
an isotopic peak from another signal (i.e. peptide specie). Third, consistency is 
primed among triplicates, so as to prioritize peaks that are consistently more 
intense. This makes the choice much more robust and avoids possible false 
positive results. And fourth, families with more than 30 members are directly 
discarded. 
Thanks to the combined use of the PAMPA and in vitro cell-based BBB assay, 
an extra selection criterion was considered. Since the PAMPA mimics only 
passive diffusion properties of the BBB, all families detected in PAMPA samples 
were hypothesized to cross the BBB through this mechanism. On the other 
hand, the in vitro cell-based BBB model mimics both active transport and 
passive diffusion properties of the BBB. It can therefore be hypothesized that 
families found in both assays cross the BBB by passive diffusion, while those 
present only in the in vitro cell-based BBB model cross by another mechanism 
(either active transport related or paracellular flux). Thus, two groups of 
peptides were generated on the basis of hypothetical passive diffusion 
permeability or other mechanisms of transport. 
After assaying the library and previous injection into the mass spectrometer, a 
sample cleaning protocol was performed. Acceptor well (baso-lateral) and t0 
samples from in vitro cell-based BBB assay were desalted with mini-C18 
columns following a standard desalting protocol. The peptides present in the 
samples were retained within mini-C18 columns and then washed with water to 
remove salts. The eluted peptides were then used for HPLC-MS analysis. 
Similarly, acceptor well and t0 PAMPA samples were cleaned following the 
same protocol. 
Once desalted, the library was injected into the LTQ-Orbitrap equipment. After 
injection, a list of all peaks and their basic information (m/z, intensity, relative 
intensity and charge) was extracted from equipment software (Figure 4). 
All data were evaluated with Bibliopepfinder to filter peaks that might 
correspond to peptides present in the Ac-D-Arg-library. Data were analyzed 
considering an instrumental error of 10 ppm. Bibliopepfinder provides output 
information for all peaks potentially corresponding to peptides belonging to the 
Ac-D-Arg-library: theoretical mass, experimental mass, amino acid composition 
(family), matching m/z signals, a general family number code and specific family 
code (e.g. (D-Glu)3-(D-Ala)1-(D-Pro)1-(D-Arg)1 family would appear as e3-a1-
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p1-r1 and general family number code would be 3111 referring to the number of 
distinct amino acids present in the family). 
The families selected from PAMPA found in all triplicates were pooled and all 
replicates were removed. Signals matching library families found in the blank 
sample (3) were subtracted from the list (Figure 5A). Finally, Bibliopepfinder 
assigned 187 families to 169 m/z signals in the LTQ-Orbitrap spectrum. 151 m/z 
signals matched a single family, while 18 m/z signals were assigned to two 
families. 
Triplicate samples from the in vitro cell-based assay analyzed by LTQ-Orbitrap 
were pooled and blank signals (10) matching possible families from the library 
were deleted (Figure 5B). Bibliopepfinder assigned 367 families to 335 m/z 
signals in the LTQ-Orbitrap spectrum. 304 m/z signals matched a single family, 
while 30 m/z signals were assigned to two families and in one case to three 
distinct families. Of the families assigned by Bibliopepfinder, 78% were present 
in all triplicates, while 15% were present in two triplicates and 7% in only one 
triplicate (Figure 5C). 
The data from the in vitro cell-based BBB model can be interpreted in two ways. 
First, it shows high reproducibility from well to well in the cell based assay  plate. 
Second, 286 out of 462 possible families in the Ac-D-Arg-library (62%) probably 
show a certain percentage of paracellular flux because the endothelial cell layer 
forming the in vitro cell-based BBB assay is too loose. This is an intrinsic 
general concern regarding the in vitro cell-based BBB models described in the 
bibliography. The improvement of this feature is currently one of the hottest 
topics in the field. 
At this point, we applied an extra selection criterion, thus generating two lists of 
candidate peptides: those postulated to cross the BBB by passive diffusion and 
those postulated to cross by other mechanisms (including active transport 
related mechanisms and paracellular flux) (Figure 5D). 
Of note, 172 (92%) out of 187 families found in PAMPA were also found in the 
in vitro cell-based BBB assay (not necessarily in all triplicates). These data 
demonstrate the satisfactory performance of this combined assay approach, 
which shows a high degree of agreement when predicting molecular passive 
diffusion properties. 
The list for “other mechanisms of transport” included signals found in all 
triplicates of in vitro cell-based BBB assay but not in PAMPA. Bibliopepfinder 
assigned 131 families to 119 m/z signals in the LTQ-Orbitrap spectrum. 108 m/z 
signals matched a single family, while 10 m/z signals were assigned to two 
families, and in one case to three distinct families. 
Selection of candidates to be further studied and validated 
We then selected some families from each list following the rational selection 
criteria stated above. The statements shown in Table 3 were applied. These 
criteria led to the selection of a set of peptides to be further studied at the 
second level of identification: 4 candidates corresponding to the “other 
mechanisms of transport” list (i3-a1-p1-r1, e2-p2-a1-r1, p2-w2-i1-r1 and i4-p1-
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r1), and 3 candidates corresponding to the “passive diffusion transport” list (i3-
p2-r1, p3-s2-r1 and a3-r2-p1). 
Skyline proteomics software was used to generate all desired transitions from 
the sequences selected. This approach allows Q-trap to monitor each transition 
in order to confirm the presence of each monitored sequence. Transitions from 
both singly and doubly charged precursor ions were monitored. On one hand, 
for singly charged precursor ions, 10 transitions were explored: b1+, b2+, b3+, b4+, 
b5+ and y5+, y4+, y3+, y2+, and y1+. On the other hand, for doubly charged 
precursor ions, 20 transitions were followed: b1+, b2+, b3+, b4+, b5+, y5+, y4+, y3+, 
y2+, y1+ and b1++, b2++, b3++, b4++, b5++, y5++, y4++, y3++, y2++, and y1++. 
To validate any sequence, transitions corresponding to the fragmentation of 
each amide bond must be found. Therefore, b1 or y5, b2 or y4, b3 or y3, b4 or y2, 
and b5 or y1 must be found to unequivocally confirm the presence of this 
sequence in the sample. These signals must not appear in the blank sample 
injected in QqQ. 
In some cases, where there are two or more equal amino acids next to each 
other, not all transitions need to be found. For example, “riiipa” could be 
assigned by finding b1 or y5, b4 or y2, and b5 or y1. However, assignments 
finding fragmentation ions that validate all transitions show greater consistency 
and robustness.  
Q-trap spectra were manually and individually assigned using Skyline 
Proteomics software. Co-elution of enough transitions (unequivocally describing 
the screened sequence) in the chromatogram ensures the presence of that 
particular sequence. Figure 6 shows, as an example, the co-elution of all 
transitions defining “raiipi” assignment to the peak at tr = 16.7 min. 
Figure 7 summarizes all the data analyzed from SRM experiments performed in 
Q-trap for all sequences of the peptide compositions selected. Information is 
filtered and rated taking into account whether identification evidence is 
consistent among triplicates, retention time, and precursor ion.  
The candidates monitored on the passive diffusion transport list suggest 
significant differences between sequences from each composition/family. From 
the i3-p2-r1 family, ripipi, rpiiip and rpipii were found in high accordance and 
consistency. Highly consistent results were found for rsppsp, rspspp and rssppp 
from the p3-s2-r1 family, and for raaarp, rraaap and rrapaa from the a3-r2-p1 
family. 
On the other hand, individual sequence evaluation from the “other mechanisms 
of transport” list showed a higher presence of sequences representing a 
specific monitored family/composition. Importantly, some of them showed high 
consistency over triplicates. In fact, i4-p1-r1 was represented by all five peptides 
sequences (riiiip, riiipi, riipii, ripiii, rpiiii), while i3-a1-p1-r1 was represented by 
rapiii, riiaip, riiiap, riiipa, riipai, riipia, ripiai, rpaiii and rpiiai. No significant 
information was found for e2-p2-a1-r1 or p2-w2-i1-r1. 
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In forthcoming stages identified peptides will be tested individually in the in vitro 
cell-based BBB assay for further validation and study of the transport 
mechanism involved. 
Conclusions 
Here we set up a novel high-throughput screening identification method based 
on mass spectrometry to identify the peptides within a library that showed 
greatest capacity to cross an in vitro BBB model (Figure 8). A workflow based 
on two MS-identification levels was established. The first MS-step consisted of 
choosing the peptides species corresponding to specific compositions (peptides 
families) by means of LTQ-Orbitrap MS, operating only on MS1 level. 
Subsequently, targeted mass spectrometry (SRM) was applied as the second 
MS-identification level by monitoring transitions defining specific amino acid 
sequences. Hence, peptide sequences (family members) within the selected 
composition were unequivocally validated. 
On the basis of data obtained from the PAMPA and the in vitro cell-based BBB 
model, we propose that some peptide families cross the BBB by passive 
diffusion transport while others use other mechanisms of transport (including 
active transport and paracellular flux). Most sequences in the i3-a1-p1-r1 and 
i4-p1-r1 families corresponding to other mechanisms of transport were validated 
in SRM experiments. Similarly, most sequences in the i3-p2-r1, p3-s2-r1 and 
a3-r2-p1 families corresponding to passive diffusion transport were also 
validated using the same experiments. 
Here we demonstrate the suitability of this novel high-throughput screening 
method for a variety of systems in which peptide libraries might be a valuable 
source of active molecules. Using specialized but widely accessible, mass 
spectrometry equipment, this approach allows the selection of the most 
promising peptide sequences interacting with or crossing an assay that mimics 
a biological target. 
 
 
Materials and methods 
Chemicals, consumables and equipment 
Protected amino acids and resins were supplied by Neosystem (Strasbourg, 
France), Calbiochem-Novabiochem AG (Laüfelfingen, Switzerland), Bachem 
AG (Bubendorf, Switzerland) and Iris Biotech, (Marktredwitz, Germany). Oxyma 
Pure (ethyl 2-cyano-2-(hydroxyimino)acetate) was provided by Luxembourg 
Industries (Tel-Aviv, Israel) and COMU by Aldrich (Milwaukee, WI USA). DIEA 
and ninhydrin were from Fluka Chemika (Buchs, Switzerland). Solvents for 
peptide synthesis and RP-HPLC were from Scharlau or SDS (Barcelona, Spain). 
Trifluoroacetic acid was purchased from KaliChemie (Bad Wimpfen, Germany). 
The other chemicals used were from Aldrich (Milwaukee, WI USA) and were of 
the highest purity commercially available. PAMPA plates and PAMPA system 
solution were from pION (Woburn, MA USA). Porcine polar brain lipid extract 
(PBLEP) was supplied by Avantis Polar Lipids (Alabaster, AL USA). HPLC 
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chromatograms were recorded on a Waters model Alliance 2695 with 
photodiode array detector 996 (Waters, Milford, USA) using a symmetry C18 
column (150 × 4.6 mm × 5 µm, 100 Å, Waters), solvents: H2O (0.045% TFA) 
and MeCN (0.036% TFA); flow rate of 1 mL/min; and software Millenium version 
4.0. HPLC-MS [Waters model Alliance 2796, quaternary pump, Waters 2487 
with UV/Vis dual absorbance detector, ESI-MS model Micromass ZQ and 
Masslynx version 4.0 software (Waters)] was done using a Symmetry 300 C18 
column (150 × 3.9 mm × 5 µm, 300 Å, Waters); solvents: H2O (0.1% formic 
acid) and MeCN (0.07% formic acid); and flow rate of 1 mL/min. All the reagents 
used for the set-up of the in vitro cell-based BBB model were supplied by 
Biological industries, Calbiochem, Gibco, Lonza, Panreac, Sigma-Aldrich and 
Worthington. Bovine brain microvascular endothelial cells were purchased from 
Cell Applications and Wistar rats from Charles River. 
Peptide library synthesis 
Library synthesis was performed using the mix-and-split [20] methodology and 
solid-phase peptide synthesis (SPPS) using the 9-
fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) strategy. In all cases peptide 
elongation and other manipulations were done manually in polypropylene 
syringes provided with porous polyethylene disks. Solvents and soluble 
reagents were removed by suction. Washings between synthetic steps were 
carried out with DMF (5 x 30 s) and DCM (5 x 30 s) using approximately 5 mL of 
solvent/g of resin. During coupling and deprotection reactions, the mixture was 
allowed to react with intermittent manual stirring (Teflon stick). Seven small 
reactors, consisting on 20-mL polypropylene syringes, each provided with a 
polyethylene porous disk, were used for coupling reactions and Fmoc group 
removal. Each 20-mL reactor was devoted to the coupling of a single amino 
acid (D-Ala, D-Arg, D-Ile, D-Glu, D-Ser, D-Trp and D-Pro). A 60-mL polypropylene 
syringe provided with a polyethylene porous disk was used as a container for 
mixing all resin for further splitting. Coupling reactions were performed with 
Fmoc-D-amino acids (4 eq.), oxima (4 eq.), COMU (4 eq.) and DIEA (8 eq.) for 
90 min. Recoupling was performed in all cases. Fmoc group deprotection was 
carried out with a solution of piperidine (20% in DMF) with one treatment of 1 
min and 2 treatments of 10 min. An additional treatment with a solution of 5% 
DBU, 20% piperidine, and 5% of toluene in DMF was applied on the D-Pro 
reactor for 1 min and two treatments of 5 min. The sixth amino acid (D-Arg), 
which is common to all peptides in the library, was coupled in the 60-mL 
reactors under the same conditions: Fmoc-D-Arg(Pbf)-OH (4 eq.), oxyma (4 eq.), 
COMU (4 eq.) and DIEA (8 eq.) with two treatments of 90 min. On the same 
reactor, acetylation was performed with acetic acid (3 eq.) and DIPCDI (6 eq.) in 
DCM with two treatments of 15 min. Prior to addition of the resin, anhydride 
formation was performed in a separate vessel. Finally, peptides were cleaved 
from the resin using a cleavage cocktail composed by TFA, TIS, and H20 
(95:2.5:2.5). Three treatments of 1 h each were performed for cleavage. 
Cleaved peptides were precipitated through addition of cold tert-butyl methyl 
ether and centrifuged at 4ºC and 4000 rpm for 10 min. The ether fraction was 
discarded and precipitation was repeated up to 3 times to remove all 
scavengers and by-products from the cleavage reaction. Finally, cleaved 
peptides were dried with a N2 flow, resuspended in H2O/MeCN (1:1), separated 
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from the resin through filtration, and finally lyophilized. Lyophilised peptides 
were redissolved with 1M HCl H2O/MeCN (1:1) and lyophilized three times to 
replace trifluoroacetate counterion for a chloride ion. 
Peptide library characterization 
Peptide library characterization was performed using two methods. 
a) Cleavage of single beads 
Proper synthesis should lead to a one-bead-one-compound library. Prior to the 
cleavage step, some resin beads were picked up and cleaved in individual vials 
with a cleavage cocktail composed by TFA, TIS, H20 (95:2.5:2.5) for 1 h. 
Cleavage cocktail was dried under a N2 flux and dissolved in H2O/MeCN (1:1). 
1 µL of peptide solution was mixed with 1 µL of ACH matrix in a MALDI-plate 
and MALDI-TOF spectra were recorded. Each peptide was analyzed by MALDI-
TOF MS in tandem mode. Analysis was performed on 15 beads, and single 
peptide sequences were characterized on each bead. 
b) Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR) 
500 µg of library sample was reconstituted in 50 µL of H2O/MeCN (1:1) with 
0.1% formic acid. Direct infusion (automated nanoelectrospray) of sample was 
performed on an LTQ-FT Ultra apparatus (Thermo Scientific). The NanoMate 
(Advion BioSciences, Ithaca, NY, USA) aspirated the samples from a 384-well 
plate (protein Lobind) by means of disposable, conductive pipette tips and 
infused the sample through the nanoESI Chip (which consists of 400 nozzles in 
a 20x20 array) towards the mass spectrometer set to positive ionization. Spray 
voltage was 1.90 kV and delivery pressure was 0.8 psi. The capillary 
temperature was 200ºC, capillary voltage 44 V and tube lens 120 V. The m/z 
range screened comprised between 200 and 1500 a.m.u. Data were acquired 
with Xcalibur software, vs.2.0SR2 (ThermoScientific). 
Primary cell lines: General considerations 
Coating of culture flask surfaces is required for proper cell seeding: poly-D-
lysine coating for astrocytes and collagen and fibronectin coatings for bovine 
brain endothelial cells. 
Poly-D-lysine coating: cell culture flasks were treated with 6 mL of poly-D-lysine 
(10 µg/mL in H2O) for 2 h at 37ºC. Poly-D-lysine solution was removed by 
suction, and flasks were left on the hood until completely dry (30 min). 
Collagen and fibronectin coating: cell culture flasks were coated by adding 6 mL 
of collagen (10 µg/mL in H2O, 0.1% v/v acetic acid) for 2 h at room temperature. 
Collagen coating solution was removed by suction and flasks were washed 
three times with PBS. Subsequently, 5 mL of fibronectin coating solution was 
added (10 µg/mL in H2O) for 30 min. Fibronectin coating solution was aspirated, 
and flasks were immediately used for cell culture purposes. 
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Three distinctly enriched DMEM (4500 mg/L glucose) standard media was used. 
DMEM (-) for rat dissection: 2 mM glutamine, 50 U/mL of penicillin, and 0.05 
g/mL streptomycin. DMEM (+) for astrocyte conditioning: 10% heat inactivated 
calf serum, 2 mM glutamine, 50 U/mL of penicillin, and 0.05 g/mL streptomycin. 
DMEM (+/+): 10% heat inactivated calf serum, 2 mM glutamine, 25 mM HEPES, 
5 mL of MEM non-essential amino acids, 50 U/mL of penicillin, and 0.05 g/mL 
streptomycin. DMEM (+/+) was used as the standard media for cell 
maintenance, both rat astrocytes and bovine brain endothelial cells. Culture 
medium was changed every other day. 
Trypsinization of cells was performed with 0.25% trypsin-EDTA for 1 min at 
37ºC. Cells were washed with DMEM (+/+) and centrifuged at 1000 rpm for 1 
min to remove all trypsin. If cells were not detached with trypsin treatment, a 
scraper was used. Cell pellet was resuspended in DMEM (+/+) and cell density 
was determined in a Neubauer counting plate. 
Astrocyte isolation 
The whole process was performed with strictly sterilized instruments. Solutions 
1 to 5 were freshly prepared the same day of dissection. Solution 1: 50 mL 
Krebs-Ringer buffer 1X, 0.15 g BSA, and 0.4 mL MgSO4 at 3.8% (w/v). Solution 
2: 10 mL solution 1, and 2.5 mg trypsin. Solution 3: 10 mL solution 1, 0.8 mg 
DNAse, 5.2 mg STBI, and 0.1 mL MgSO4 at 3.8% (w/v). Solution 4: 8.4 mL 
solution 1 and 1.6 mL of solution 3. Solution 5: 5 mL solution 1, 40 µL MgSO4 at 
3.8% (w/v), and 6 µL CaCl2 at 1.2% (w/v). Six newborn Wistar rats (2 
pups/flask) at the age of 2 to 3 days were decapitated with scissors and each 
head was dipped in a 70% ethanol solution. The brains were extracted from the 
skulls and placed on a petri dish containing ice-cold DMEM (-). The cortex of 
each brain was carefully isolated and meninges were peeled out. Cortexes 
were pulled, chopped with a blade, and transferred with a pipette to a   50-mL 
centrifuge tube, together with solution 1. The mixture was centrifuged at 4ºC 
and 1000 rpm for 5 sec. The supernatant was discarded and solution 2 was 
added. The mixture was carefully shaken at room temperature for 5 min, after 
which solution 4 was added, and the mixture was centrifuged at 4ºC and 1000 
rpm for 5 sec. The supernatant was discarded, and two Pasteur pipette volumes 
of solution 3 were added. The pellet was resuspended and thoroughly 
homogenized using a Pasteur pipette with a narrowed end. Solution 5 was 
added to the homogenized mixture. The mixture was centrifuged at 4ºC and 
1000 rpm for 5 min. The supernatant was discarded and the pellet was carefully 
resuspended in DMEM (+) and seeded in three p75 cell culture flasks. Cell 
cultures were maintained at 37ºC and 5% CO2 for 3 days (it is highly 
recommended not to manipulate flasks during the first three days), when culture 
media had to be replaced. At day 6, culture media was renewed, and cell 
cultures were shaken at 90 rpm under anaerobic conditions overnight. Culture 
media were removed, and cells still attached to the flasks were carefully rinsed 
with PBS and cultured again with DMEM (+)at 37ºC and 5% CO2 until day 9. 
Astrocytes were subcultured in p75 culture flasks previously coated with poly-D-
lysine. 
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All experiments using rats were approved by the appropriate institutional review 
committee and performed in strict compliance with the European Community 
Guide for the Care and Use of Laboratory Animals. 
Construction of in vitro cell-based BBB model  
The established model consists of a co-culture of bovine brain endothelial cells 
and rat astrocytes. The model was built on 24-well plates containing inserts or 
transwells containing a polycarbonate membrane with a surface area of 0.33 
cm2 and pore-size of 0.4 µm. The upper surface of transwells was coated with 
collagen type IV and fibronectin. First, filter membranes were incubated with 
100 µL of collagen type IV solution (10 µg/mL) in H2O (0.1% v/v acetic acid) for 
2 h at room temperature. Transwells were rinsed three times with PBS to 
remove traces of acetic acid, and 100 µL of fibronectin solution (100 µg/mL in 
PBS) was added for transwell membrane coating for 30 min at room 
temperature, after which the solution was removed by suction. Transwells were 
placed upside down in plastic boxes containing 10 mL of PBS in order to 
maintain high relative humidity inside the box. Immediately, 90-µL droplets 
containing approximately 45000 astrocytes were seeded on the bottom part of 
each filter. Astrocytes were incubated upside down for 75 min. Fresh DMEM 
was added to each filter every 15 min. Inserts were carefully transferred to the 
24-well plate containing 800 µL of DMEM media. The upper well was filled with 
200 µL of DMEM. The transwell system was incubated at 37ºC and 5% CO2 for 
3 days. It is highly recommended not to manipulate transwell system during the 
first three days. Medium was changed by enriched differentiation medium 
(clonetics EMVB SingleQuots, Lonza) with heparin (125 µg/mL in PBS, freshly 
prepared), HEPES (25 mM in PBS) and MEM (10 µL/mL) 2 h prior to seeding 
the bovine brain endothelial cells. 45000 cells contained in droplets of 20 µL 
were seeded in the upper part of the filter. Cells were homogeneously 
distributed across the membrane by carefully pipetting up and down the upper 
transwell suspension. The transwell system was incubated at 37ºC and 5% CO2 
for three days. At day 3 of co-culture, medium was replaced by differentiation 
medium (clonetics EMVB SingleQuots, Lonza) supplemented with 8-(4-
chlorophenylthio)-cAMP (154 mg/L in H2O) and 4-(3-butoxy-4-methoxybenzyl)-
2-imidazolidinone (4.9 mg/L in DMSO) and incubated at 37ºC and 5% of CO2. 
In general, at day 8 of co-culture, the system was ready to perform transport 
studies. To assess the maturity of the cell layer transendothelial electrical 
resistance measurements (TEER) were performed. 
Transport assay: in vitro blood-brain barrier model  
Inserts were washed with Ringer/HEPES solution. Acceptor (lower or baso-
lateral) compartments were filled with 0.8 mL of Ringer/HEPES solution, while 
the donor compartments (upper or apical) were filled with 0.2 mL of peptides 
dissolved in Ringer/HEPES. The assay was performed for 2 h, incubating the 
plate at 37ºC and 5% CO2. Assayed peptides were co-incubated with 20 µM of 
Lucifer Yellow (LY). After the experiment, LY permeability was determined by 
transferring an aliquot of the samples to a fluorescence plate reader (excitation 
at 428 nm and emission at 536 nm). A LY permeability over 1.710-5 cm/s 
indicates cell membrane disruption or breakage during the assay, and such 
wells discarded. 
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? · ?? 
where (dQ/dt) is the amount of sample present in the acceptor compartment in 
function of time (nmol/s), A is the area of the insert (cm2), and C0 is the initial 
concentration of sample applied to the donor compartment (nmol/mL). 
The percentage of transport is calculated using the following equation: 
%? = ??(?)??(??) · 100 
where QA(t) is the compound concentration in the acceptor well at time t and 
QD(t0) is the compound concentration in the donor well at t = 0. 
All samples were tested in triplicate. The Ac-D-Arg-library was tested at 10% of 
saturation concentration. 
Transport assay: Parallel artificial membrane permeability assay 
The parallel artificial membrane permeability assay (PAMPA) was used to 
assess the capacity of the peptides to cross the BBB by passive diffusion by 
means of effective permeability (Pe). The initial concentration of compounds 
was set at 200 µM in a buffer solution prepared by dilution from a commercial 
buffer solution by pION, following the manufacturer’s instructions. The PAMPA 
sandwich consists of two 200-µM wells separated by a polycarbonate filter 
membrane, which is coated with 4 µL of phospholipids in dodecane (20 mg/mL). 
Peptide sample (195 µL) was placed in the donor compartment (lower) 
containing a magnetic seed, while the acceptor compartment (upper) was filled 
with 200 µL of plain buffer. The plate was covered and incubated at room 
temperature in a saturated humidity atmosphere for 4 h in Gut-Box™ chamber 
at 25 µm of unstirred water layer (UWL). The content of acceptor and donor 
compartments was evaluated by HPLC-UV or by MALDI-TOF, and Pe, 








%? = ??(?)??(??) · 100 
%	????????	????????? = [??(??) − ??(?) − ??(?)] · 100 
Off-line reverse phase purification protocol 
Selected columns (Ultra MicroSpin C18, 300Å silica (5-60 µg) commercial 
column) were conditioned with 200 µL of “conditioning buffer” (MeOH) two times, 
and spun in a centrifuge (1000 x g for 1 min) to push the flow through. The 
column was equilibrated with 200 µL “equilibration buffer” three times with 
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spinning. Peptide samples were dissolved in H2O (with 5% formic acid) and 
loaded onto the column. Washing buffer was applied to the column three times 
(200 µL), and finally peptides were eluted with three treatments of 200 µL of 
“elution buffer”. Solvent from eluted peptides was evaporated using a 
SpeedVac system. Samples were dissolved in 40 µL of 0.1% formic acid for 
injection. Conditioning buffer: 100% methanol. Equilibration/washing buffer: 5% 
formic acid in H2O. Elution buffer: 5% formic acid in H2O /MeCN (1:1, v/v). 
Sample treatment before HPLC-MS injection 
Acceptor samples and t0 samples from the PAMPA assay and in vitro cell-
based BBB assay were evaporated using a SpeedVac system. Samples were 
redissolved in 200 µL of H2O (with 5% formic acid) and desalted with off-line 
reverse phase purification. 
LTQ-Orbitrap-XL 
Library peptides were analyzed using a LTQ-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA, USA) coupled to an Agilent 
Technologies 1200 Series (CA, USA). Peptides were loaded onto C18 Zorbax 
precolumn (Agilent Technologies, cat #5065-9913) and separated by reverse-
phase chromatography using a 12-cm column with an inner diameter of 75 µm, 
packed with 5 µm C18 particles (Nikkyo Technos Co., Ltd. Japan). 
Chromatographic gradients started at 97% buffer A and 3% buffer B with a flow 
rate of 300 nL/min, and gradually increased to 90% buffer A and 10% buffer B 
in 1 min, and to 65% buffer A / 35% buffer B in 30 min. After each analysis, the 
precolumn and column were washed for 10 min with 10% buffer A / 90% buffer 
B. Buffer A: 0.1% formic acid in H2O. Buffer B: 0.1% formic acid in MeCN. 
The mass spectrometer was operated in positive ionization mode with 
nanospray voltage set at 2.5 kV and source temperature at 200 °C. Ultramark 
1621 for the FT mass analyzer was used for external calibration prior to the 
analyses. Moreover, an internal calibration was also performed using the 
background polysiloxane ion signal at m/z 445.1200. Full MS scans with 1 micro 
scans at resolution of 60000 were used over a mass range of m/z 350-2000 
with detection in the Orbitrap to obtain the exact mass of peptide precursors. 
Auto gain control (AGC) was set to 1106, dynamic exclusion (60 seconds). All 
data were acquired with Xcalibur software v2.2. 
Q-trap 
The peptide mixtures were analyzed using a 5500 Q-trap mass spectrometer 
(AB Sciex, Framingham, MA, USA) coupled to a nanoLC Ultra-1DPlus (AB 
Sciex (Eksigent)). Peptides were loaded onto C18 Acclaim PepMap precolumn 
(Thermo Scientific, cat # 164564) and separated by reverse-phase 
chromatography using a 12-cm column with an inner diameter of 75 µm, packed 
with 5-µm C18 particles (Nikkyo Technos Co., Ltd. Japan). Chromatographic 
gradients started at 98% buffer A and 2% buffer B with a flow rate of 300 nL/min 
for 5 min and gradually increased to 60% buffer A and 40% buffer B in 35 min. 
After each analysis, the precolumn and column were washed for 10 min with 
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2% buffer A / 98% buffer B. Buffer A: 0.1% formic acid in H2O. Buffer B: 0.1% 
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Figure 1. A) General structure of the synthesized mix-and-split peptide library. 
B) Set of selected amino acids used for the synthesis of the mix-and-split 
peptide library. This library design leads to 16.807 peptides (R = rm; where r is 
the number of amino acids used to introduce variability, and m is the number of 
peptide residue positions where variability is introduced). C) Mix and split SPPS 
Ac-D-Arg-library synthetic workflow. Library synthesis was performed by the 
mix-and-split methodology in SPPS, using Rink-amide AM resin (200 mesh). 
Synthetic workflow comprises 5 rounds of mix-and-split. Each round involved 
dividing the resin in a large vessel into 7 smaller reactors, coupling amino acid 
building blocks, Fmoc deprotection, and mixing the resin again in the large 
vessel. Once five residues were coupled, a final coupling step was performed in 
the larger vessel to introduce Fmoc-D-Arg(Pbf)-OH as the N-terminus amino 
acid in all peptides of the library. Finally, the whole library was N-terminus-
acetylated and cleaved from the resin. 
 
Figure 2. Comparison of relative abundance of the library peptides in theoretical 
and experimental spectra recorded by FT-ICR mass spectrometrer, up and 
upside down respectively. 
Figure 3. A) Scheme of PAMPA. An artificial phospholipid membrane mimics 
only passive diffusion properties of the BBB. The thickness of the 
phospholipidic membrane has been described to be equivalent to 300 lipid 
bilayers. B) Scheme of in vitro cell-based BBB assay. A co-culture of bovine 
brain endothelial cells and rat astrocytes provides an assay mimicking both 
passive diffusion and active related transports mechanisms described in the 
BBB. 
Figure 4. General workflow followed to obtain peptide composition lists (peptide 
families). Molecular ions from all MS1 spectra recorded throughout the total ion 
chromatogram (TIC) chromatogram matching peptides masses within Ac-D-Arg-
library are selected by Bibliopepfinder. 
Figure 5. Venn diagrams showing relations between sets of experimental data: 
A) PAMPA library sample vs. PAMPA blank sample. B) In vitro cell-based BBB 
assay library sample vs. in vitro cell-based BBB assay blank sample. C) 
Triplicate samples from in vitro cell-based BBB assay. D) PAMPA library 
sample vs. in vitro cell-based BBB assay sample. 
Figure 6. Case example (raiipi), the process followed for each single targeted 
sequence to search for complete sets of co-eluting transitions. A, B and C 
correspond to the SRM spectra and zoom in images of the same spectra. A 
also shows the blank spectra monitoring the same sequence. 
Figure 7. Summarized information extracted from SRM experiments performed 
in Q-trap. Information shown in the table refers to co-eluting transitions found in 
triplicate samples and the retention time at which they were found. No 
significant information was found for e2-p2-a1-r1 or p2-w2-i1-r1. 
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Figure 8: General scheme of proposed novel high-throughput screening 
methodology based on mass spectrometry. Mix-and-split methodology was 
applied on SPPS for library synthesis. The library was subsequently assayed in 
an in vitro cell-based BBB model consisting of a co-culture of bovine brain 
endothelial cells and rat astrocytes. Concerning peptide identification, mass 
spectrometry techniques were used. A workflow based on two MS-identification 
levels was set up. 1) First MS-identification step involving the selection of the 
most promising peptide species corresponding to specific compositions (peptide 
families) with LTQ-Orbitrap MS, only operating on MS1 level. 2) Subsequently, 
targeted mass spectrometry (SRM) was applied as the second MS-identification 
level by monitoring transitions defining specific amino acidic sequences. Hence, 
peptide sequences (family members) comprised within the selected composition 
can be unequivocally validated. RAIIPI is shown as an example. 
 
Table 1. Summary of parameters considered for the selection of a reduced 
amino acid set. Second column in the table shows the propensity of each amino 
acid to form a secondary structure: α-helix and β-sheet. Symbol ≈ indicate a 
similar value for α-helix and β-sheet structures; ≈β a medium propensity to form 
a β-sheet; and α and β high propensity to form α-helix and β-sheet, respectively. 
The third column shows the hydrophobicity of selected amino acids in the Kyte-
Doolittle scale. Selected amino acids include hydrophobic, hydrophilic and 
neutral molecules. The fourth column shows the percentage of amino acid 
presence in active sites with respect to the total number of selected amino acids 
in the sequence. Alanine value is not known since alanine scanning was the 
methodology to calculate this parameter. This amino acid set includes 3 top 
amino acids on this parameter: Trp, Arg and Ile. Furthermore, proline was 
included in these selections since it is the only proteinogenic N-alkyl amino acid. 
Table 2. Family column stands for a general molecular formula code expressing 
the variety of amino acids and their repetition, which determine the number of 
possible family member columns for all families comprised within the library. 
Table 3. Selection criteria for peptide composition/family selection for further 
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1. 5x1 min DMF
2. 5x1 min DCM
20% piperidine, DMF
1x1 min, 2x10 min
Fmoc-Aa-OH (4 eq)
Oxima Pure (4 eq)
COMU (4 eq)
DIEA (8 eq), DMF
1x90 min
i) 20% piperidine, DMF
1x1 min, 2x10 min
ii) Only Pro reactor:
5% DBU, 20% piperidine,
5% toluene, DMF
1x1 min, 2x5 min
Fmoc-Aa-OH (4 eq)
Oxima Pure (4 eq)
COMU (4 eq)








i) Fmoc-D-Arg(Pbf)-OH (4 eq)
Oxima Pure (4 eq)
COMU (4 eq)
DIEA (8 eq), DMF
2x90 min
ii) 20% piperidine, DMF
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Preferences in hot 
spots (%) [22] 
D-Trp ≈β -0.9 21.05 
D-Arg ≈ -4.5 13.30 
D-Ala α 1.8 - 
D-Glu α -3.5 3.64 
D-Ser ≈ -0.8 1.12 
D-Ile β 4.5 9.62 
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1 - Must be in all triplicates. 
2 - Its molecular peak must have a typical mass ratio profile in mass 
spectrometry of peptide species in the MS1 LTQ-Orbitrap spectra. 
3 - Apply a score criterion based on weighted intensity ranking on all triplicates. 
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Figure 2. Comparison of relative abundance of the library peptides in theoretical and experimental spectra 
recorded by FT-ICR mass spectrometrer, up and upside down respectively.  
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Figure 3. A) Scheme of PAMPA. An artificial phospholipid membrane mimics only passive diffusion properties 
of the BBB. The thickness of the phospholipidic membrane has been described to be equivalent to 300 lipid 
bilayers. B) Scheme of in vitro cell-based BBB assay. A co-culture of bovine brain endothelial cells and rat 
astrocytes provides an assay mimicking both passive diffusion and active related transports mechanisms 
described in the BBB.  
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Figure 4. General workflow followed to obtain peptide composition lists (peptide families). Molecular ions 
from all MS1 spectra recorded throughout the total ion chromatogram (TIC) chromatogram matching 
peptides masses within Ac-D-Arg-library are selected by Bibliopepfinder.  
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Figure 5. Venn diagrams showing relations between sets of experimental data: A) PAMPA library sample vs. 
PAMPA blank sample. B) In vitro cell-based BBB assay library sample vs. in vitro cell-based BBB assay blank 
sample. C) Triplicate samples from in vitro cell-based BBB assay. D) PAMPA library sample vs. in vitro cell-
based BBB assay sample.  
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Figure 6. Case example (raiipi), the process followed for each single targeted sequence to search for 
complete sets of co-eluting transitions. A, B and C correspond to the SRM spectra and zoom in images of the 
same spectra. A also shows the blank spectra monitoring the same sequence.  
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Figure 7. Summarized information extracted from SRM experiments performed in Q-trap. Information shown 
in the table refers to co-eluting transitions found in triplicate samples and the retention time at which they 
were found. No significant information was found for e2-p2-a1-r1 or p2-w2-i1-r1.  
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Figure 8: General scheme of proposed novel high-throughput screening methodology based on mass 
spectrometry. Mix-and-split methodology was applied on SPPS for library synthesis. The library was 
subsequently assayed in an in vitro cell-based BBB model consisting of a co-culture of bovine brain 
endothelial cells and rat astrocytes. Concerning peptide identification, mass spectrometry techniques were 
used. A workflow based on two MS-identification levels was set up. 1) First MS-identification step involving 
the selection of the most promising peptide species corresponding to specific compositions (peptide families) 
with LTQ-Orbitrap MS, only operating on MS1 level. 2) Subsequently, targeted mass spectrometry (SRM) 
was applied as the second MS-identification level by monitoring transitions defining specific amino acidic 
sequences. Hence, peptide sequences (family members) comprised within the selected composition can be 
unequivocally validated. RAIIPI is shown as an example.  
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